Alzheimer's Disease Trial, Recruiting NCT05288842 Sponsor: University Hospital, Lille Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT05288842
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to have a lumbar puncture (a procedure to collect fluid from the spine)
  • People who are registered with the French Social Security system

Group 1 – Healthy Controls (no memory problems):

  • People who have no memory complaints, based on a memory complaint questionnaire
  • People with normal cognitive (thinking and memory) test scores for their age and education level
  • People who are willing and able to follow the study procedures and sign a consent form after being fully informed

Group 2 – Alzheimer's Disease:

  • People who have been diagnosed with probable Alzheimer's disease dementia, according to recognised 2011 medical guidelines
  • People who score 16 or above on a standard memory and thinking test (MMSE)
  • People who have a study partner (a friend or family member) who can complete some questionnaires and provide a lift home after the lumbar puncture — if neither the participant nor the study partner can drive, travel costs will be covered by the study organiser
  • People (and their study partners) who are willing and able to follow the study procedures and sign a consent form; a legal representative may assist with this process if needed

Group 3 – Frontotemporal Dementia:

  • People who have been diagnosed with probable frontotemporal dementia, according to recognised 2011 medical guidelines
  • People who score 16 or above on a standard memory and thinking test (MMSE)
  • People who have a study partner (a friend or family member) who can complete some questionnaires and provide a lift home after the lumbar puncture — if neither the participant nor the study partner can drive, travel costs will be covered by the study organiser
  • People (and their study partners) who are willing and able to follow the study procedures and sign a consent form; a legal representative may assist with this process if needed

Who may not be able to join:

  • People whose dementia is caused by something other than a brain-degenerating condition, including those with a heavy burden of blood vessel disease in the brain
  • People who have a medical reason that prevents them from having a lumbar puncture
  • People who have a medical reason that prevents them from having an MRI scan
  • People who weigh less than 45 kg
  • People who have another brain-degenerating condition, such as Lewy body dementia or Parkinson's disease
  • People who have another serious brain or nervous system condition, such as a brain tumour, stroke, epilepsy, or fluid build-up on the brain
  • People with a serious metabolic or hormonal disorder (though stable, well-controlled hypothyroidism, type 2 diabetes, or common cholesterol problems may be acceptable — confirm with trial site)
  • People who take the medication metformin
  • People with a known active hepatitis C (HCV), hepatitis B (HBV), or HIV infection
  • People with significant abnormal blood test results, either previously known or found at the screening appointment, based on the doctor's assessment
  • People who are pregnant, breastfeeding, or women of childbearing age who are not using effective contraception (a pregnancy test will be carried out)
  • People with excessive alcohol intake or drug misuse, based on the doctor's assessment
  • People who, in the doctor's opinion, are unlikely to be able to follow the study procedures, or who cannot be contacted in an emergency

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Thibaud LEBOUVIER, MD,PhD, University Hospital, Lille

Phone: 0320445962

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
6 September 2022
Est. completion
1 October 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Mean CSF-to-blood ratio (CBR) of leptin concentration.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov